---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-002707"
form_type: "8-K"
ticker: "CORT"
cik: "0001088856"
company_name: "CORCEPT THERAPEUTICS INC"
filed_at: "2022-02-15T23:59:59+00:00"
generated_at: "2026-06-27T07:50:23.051981+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Corcept Q4 revenue $98.8M, net income $32.1M; guides 2022 rev $400-430M

## Summary
- Q4 revenue $98.8M (+15% YoY); FY2021 revenue $366M (+3.4% from $353.9M).
- Q4 GAAP net income $32.1M (vs $26M); FY GAAP net income $112.5M (vs $106M). Non-GAAP Q4 $42.6M.
- 2022 revenue guidance $400-430M, implying 9-17% growth.
- Repurchased 10M shares for $207.5M in Q4; cash+investments $335.8M.
- Clinical: ovarian cancer Phase 3 start Q2 2022; AIWG Phase 2 data Q4 2022; NDA for Cushing's Q2 2023.

## SEC filing metadata
- accession: 0001628280-22-002707
- form_type: 8-K
- ticker: CORT
- cik: 0001088856
- company_name: CORCEPT THERAPEUTICS INC
- filed_at: 2022-02-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1088856/000162828022002707/0001628280-22-002707-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1088856/000162828022002707/cort-20220215.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-002707
- JSON: https://secwatch.observer/filing/0001628280-22-002707.json
- Plain text: https://secwatch.observer/filing/0001628280-22-002707.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.